Canna~Fangled Abstracts

Pharmacological Foundations of Cannabis Chemovars.

By November 21, 2017 No Comments
Planta Med. 2017 Nov 21. doi: 10.1055/s-0043-122240.
[Epub ahead of print]

Abstract

PM 2 site 207An advanced Mendelian Cannabis breeding program has been developed utilizing chemical markers to maximize the yield of phytocannabinoids and terpenoids with the aim to improve therapeutic efficacy and safety. Cannabis is often divided into several categories based on cannabinoid content. Type I, Δ9-tetrahydrocannabinol-predominant, is the prevalent offering in both medical and recreational marketplaces. In recent years, the therapeutic benefits of cannabidiol have been better recognized, leading to the promotion of additional chemovars: Type II, Cannabis that contains both Δ9-tetrahydrocannabinol and cannabidiol, and cannabidiol-predominant Type III Cannabis. While high-Δ9-tetrahydrocannabinol and high-myrcene chemovars dominate markets, these may not be optimal for patients who require distinct chemical profiles to achieve symptomatic relief. Type II Cannabis chemovars that display cannabidiol- and terpenoid-rich profiles have the potential to improve both efficacy and minimize adverse events associated with Δ9-tetrahydrocannabinol exposure. Cannabis samples were analyzed for cannabinoid and terpenoid content, and analytical results are presented via PhytoFacts, a patent-pending method of graphically displaying phytocannabinoid and terpenoid content, as well as scent, taste, and subjective therapeutic effect data. Examples from the breeding program are highlighted and include Type I, II, and III Cannabis chemovars, those highly potent in terpenoids in general, or single components, for example, limonene, pinene, terpinolene, and linalool. Additionally, it is demonstrated how Type I - III chemovars have been developed with conserved terpenoid proportions. Specific chemovars may produce enhanced analgesia, anti-inflammatory, anticonvulsant, antidepressant, and anti-anxiety effects, while simultaneously reducing sequelae of Δ9-tetrahydrocannabinol such as panic, toxic psychosis, and short-term memory impairment.

PMID: 29161743
DOI: 10.1055/s-0043-122240

Conflict of interest statement

Conflict of Interest: MA Lewis is President of Napro Research, a company engaged in phytochemical analysis and research, and the developer of the PhytoFacts report format. EB Russo former Medical Director of Phytecs, a company investigating the therapeutic applications of Cannabis, other botanicals and dietary approaches affecting the endocannabinoid system and is currently the director of research and development at the International Cannabis and Cannabinoid Institute (ICCI). KM Smith is Laboratory Director of Napro Research. Several of the plant chemovars herein may be subject to one or more issued or published U. S. patent applications.
twin memes II
en English